Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital upgrades ASOS on H1 profit beat

(Sharecast News) - Shore Capital has upgraded ASOS from 'hold' to 'buy' after first-half earnings came in ahead of forecasts on Friday. The broker said it sees a "better entry point" for investors with the stock having fallen to its 2008 lows, trading at an enterprise-value-to-EBITDA ratio of just 4x, compared with a peer average multiple of 12x.

ASOS said that EBITDA for the six months to 3 March would be ahead of the £34m consensus estimate due to strong gross margin development, driven by lower markdown activity and increased full-price mix, and continued cost discipline.

"Improving profitability has been a key focus for the group, with successful efforts made to reduce inventory levels and allow ASOS to operate from a more agile business model. Note Test & React now makes up more than 15% of own-brand sales and is said to be growing," Shore Capital said in a research note.

Nevertheless, the broker said it continues to be "concerned" about top-line headwinds, and so will be watching key customer metrics closely when interim results are announced on 24 April.

"Whilst we continue to state some caution relating to market pressures and customer trends, the recent balance sheet actions and progress the group has made to support profits are encouraging," Shore Capital said.

ASOS shares were up 23.5% at 315p by 0957 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.